The massive financial investments in the development and clinical establishment of 18F-radioligands for the quantification of β-amyloid plaques and tau proteins using PET are showing high confidence in this cutting-edge technology, triggering new evidence-based early diagnosis approaches and the systematic development of clinically useful prediction markers in AD. The gene discussed is MAPT; the disease is Alzheimer disease.